NCT00403845View on ClinicalTrials.gov

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Indacaterol 150 μg

Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

DRUG

Indacaterol 300 μg

Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

DRUG

Placebo

Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).

Trial Locations (8)

Unknown

Novartis Investigative site, Kasukabe

Novartis Investigator Site, Kishiwada

Novartis Investigative Site, Kurume

Novartis Investigative Site, Obihiro

Novartis Investigative Site, Sagamihara

Novartis Investigative Site, Sapporo

Novartis Investigator Site, Tokyo

Novartis Investigative Site, Wakayama

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY